AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance

AbbVie (NYSE: ABBV) reported Q3 EPS of $2.95, $0.08 better than the analyst estimate of $2.87. Revenue for the quarter came in at $13.93 billion versus the consensus estimate of $13.71 billion.

GUIDANCE:

AbbVie sees Q4 2023 EPS of $11.19-$11.23, versus the consensus of $11.06.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Abbvie (ABBV) PT Raised to $273 at Canaccord
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• EU approves AbbVie's Maviret for acute hepatitis C treatment